IL-22 unlocks large-scale in vitro hepatocyte expansion via STAT3 activation
- 2 April 2026
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (6) , 1024-1027
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism
This publication has 19 references indexed in Scilit:
- IL-22 supports long-term expansion of mouse and human hepatocytesJournal of Hepatology, 2026
- An Update on IL-22 Therapies in Alcohol-Associated Liver Disease and BeyondThe American Journal of Pathology, 2025
- The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based designImmunity, 2021
- An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated HepatitisHepatology, 2020
- Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in miceJournal of Hepatology, 2020
- Interleukin‐22 Ameliorates Neutrophil‐Driven Nonalcoholic Steatohepatitis Through Multiple TargetsHepatology, 2020
- Interleukin-22 from bench to bedside: a promising drug for epithelial repairCellular & Molecular Immunology, 2018
- Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3Hepatology, 2011
- In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progressionHepatology, 2011
- In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats1 1The authors thank Tim Lee (Moor Instruments Ltd., Millwey, United Kingdom) for assistance with Laser Doppler Image analysis.Gastroenterology, 2003